LT4087879T - Antikūnai prieš muci-sea - Google Patents

Antikūnai prieš muci-sea

Info

Publication number
LT4087879T
LT4087879T LTEPPCT/IL2021/050269T LTIL2021050269T LT4087879T LT 4087879 T LT4087879 T LT 4087879T LT IL2021050269 T LTIL2021050269 T LT IL2021050269T LT 4087879 T LT4087879 T LT 4087879T
Authority
LT
Lithuania
Prior art keywords
muci
sea antibodies
sea
antibodies
Prior art date
Application number
LTEPPCT/IL2021/050269T
Other languages
English (en)
Lithuanian (lt)
Inventor
Daniel Rubinstein
Daniel Wreschner
Original Assignee
Biomodifying Llc
Ramot At Tel-Aviv University Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomodifying Llc, Ramot At Tel-Aviv University Ltd. filed Critical Biomodifying Llc
Publication of LT4087879T publication Critical patent/LT4087879T/lt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
LTEPPCT/IL2021/050269T 2020-03-18 2021-03-11 Antikūnai prieš muci-sea LT4087879T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062991077P 2020-03-18 2020-03-18
PCT/IL2021/050269 WO2021186427A1 (en) 2020-03-18 2021-03-11 Anti- muc1-sea antibodies

Publications (1)

Publication Number Publication Date
LT4087879T true LT4087879T (lt) 2026-08-10

Family

ID=75439163

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/IL2021/050269T LT4087879T (lt) 2020-03-18 2021-03-11 Antikūnai prieš muci-sea

Country Status (23)

Country Link
US (1) US20230085269A1 (cg-RX-API-DMAC7.html)
EP (1) EP4087879B1 (cg-RX-API-DMAC7.html)
JP (1) JP7828286B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220161267A (cg-RX-API-DMAC7.html)
CN (1) CN115667312A (cg-RX-API-DMAC7.html)
AU (1) AU2021239078A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018629A2 (cg-RX-API-DMAC7.html)
CA (1) CA3171531A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002520A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014726A2 (cg-RX-API-DMAC7.html)
CR (1) CR20220523A (cg-RX-API-DMAC7.html)
CU (1) CU20220055A7 (cg-RX-API-DMAC7.html)
DK (1) DK4087879T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2022000193A (cg-RX-API-DMAC7.html)
EC (1) ECSP22080687A (cg-RX-API-DMAC7.html)
FI (1) FI4087879T3 (cg-RX-API-DMAC7.html)
IL (1) IL296572A (cg-RX-API-DMAC7.html)
LT (1) LT4087879T (cg-RX-API-DMAC7.html)
MX (1) MX2022011553A (cg-RX-API-DMAC7.html)
PE (1) PE20230602A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022552445A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021186427A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202211303B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4676975A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 and cd16a antibodies and methods of use
TW202436357A (zh) * 2023-03-03 2024-09-16 瑞士商百濟神州瑞士有限責任公司 Muc1抗體及使用方法
AU2024318998A1 (en) 2023-07-31 2026-01-22 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate
WO2026078593A1 (en) 2024-10-08 2026-04-16 Sun Pharma Advanced Research Company Limited Sting agonists and antibody drug conjugates thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Aβオリゴマーに特異的に結合する抗体およびその利用
ES2823351T3 (es) * 2013-12-19 2021-05-06 Arocell Ab Anticuerpos anti-TK1 monoclonales
RU2746413C1 (ru) * 2017-03-21 2021-04-13 Пептрон, Инк. Антитело, специфически связывающееся с muc1, и его применение
WO2018174544A2 (ko) 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
US11970542B2 (en) 2017-11-08 2024-04-30 Fred Hutchinson Cancer Center Bispecific antibodies specific for treating hematological malignancies

Also Published As

Publication number Publication date
WO2021186427A1 (en) 2021-09-23
BR112022018629A2 (pt) 2023-03-07
KR20220161267A (ko) 2022-12-06
CN115667312A (zh) 2023-01-31
IL296572A (en) 2022-11-01
DK4087879T3 (en) 2026-07-27
PE20230602A1 (es) 2023-04-10
AU2021239078A1 (en) 2022-08-11
JP2023517754A (ja) 2023-04-26
JP7828286B2 (ja) 2026-03-11
CO2022014726A2 (es) 2023-02-16
ECSP22080687A (es) 2022-12-30
MX2022011553A (es) 2023-01-04
ZA202211303B (en) 2025-08-27
FI4087879T3 (fi) 2026-07-22
CR20220523A (es) 2023-01-23
EP4087879B1 (en) 2026-05-06
CA3171531A1 (en) 2021-09-23
EP4087879A1 (en) 2022-11-16
PH12022552445A1 (en) 2023-11-20
CL2022002520A1 (es) 2023-03-10
US20230085269A1 (en) 2023-03-16
DOP2022000193A (es) 2023-03-23
CU20220055A7 (es) 2023-06-13